To verify the activation of these kinds of proteins, Nano-LC-MS/MS, qRT-PCR and western blot were employed to validate the differential expression of hnRNPA2B1, hnRNPD, hnRNPL and YBX-1 in ten pooled or individual GC patients’ tissue samples. The gene discussed is HNRNPA2B1; the disease is gastric cancer.